Drugmaker touts benefits of fish oil derivative, experts reserve judgment

Irish pharmaceutical company Amarin sent a ...

Posted: Sep 25, 2018 12:33 PM
Updated: Sep 25, 2018 12:33 PM

Irish pharmaceutical company Amarin sent a glowing announcement to investors Monday that its drug Vascepa, a purified fish oil derivative, was linked to a 25% reduced risk of major cardiovascular events such as heart attack and stroke.

While some doctors saw this announcement as a stunning and unexpected result that could change medical practice, others are reserving their judgment until the company shares its data, which have not been published in a peer-reviewed journal.

Business and industry sectors

Business, economy and trade

Consumer products

Fats and oils

Food and drink

Food products

Kinds of foods and beverages

Banking, finance and investments

Cardiology

Cardiovascular disease

Derivatives markets

Diseases and disorders

Drug safety

Drug safety, efficacy and availability

Financial markets and investing

Health and medical

Medical fields and specialties

Pharmaceutical industry

Pharmaceuticals and biotechnology

Pharmaceuticals and prescription drugs

Securities trading

Energy and utilities

Oil and gas industry

"This trial certainly strengthens the idea that treating people with cardiovascular disease [and] with elevated triglycerides resulted in a reduction in cardiovascular events," said Dr. Howard Weintraub, a preventive cardiologist and clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Health. Weintraub was a co-investigator of the trial.

But experts say these findings were not widely expected. The science behind fish oil and cardiovascular health has been inconclusive, and many studies have not shown a benefit. Vascepa is derived from a single omega-3 fatty acid isolated from fish.

"I want to see the numbers," said cardiologist Dr. Russell Luepker, a Mayo professor of public health at the University of Minnesota who was not involved in the trial. "This is just a tiny fraction of the data that they undoubtedly have. And undoubtedly what they've given us is the best data they have.

"This is almost like a press release to generate buzz."

Amarin shares closed on Friday at $2.99, opened Monday above $10 and rose throughout the day.

Cardiologist Dr. Rita Redberg described the announcement as "remarkably free of data" and said that initial buzz surrounding drug-related announcements hasn't always panned out.

"This is potentially very interesting. I just don't think there's enough here to know," said Redberg, also a professor of medicine at the University of California, San Francisco.

In its statement, the drug maker also cautioned, "Existing and prospective investors are cautioned not to place undue reliance on topline results."

More results from the trial will be presented on November 10 at a meeting of the American Heart Association in Chicago. Investigators say they also plan to publish the results in a peer-reviewed journal, according to the company statement.

Weintraub said that the trial could have succeeded where others failed for three reasons: the specific fish oil component they used, the higher dose of four grams per day and the type of patient it was given to.

The 8,179 patients in the double-blinded study had LDL levels in the normal range, controlled by statins, as well as "persistent elevated triglycerides," another kind of lipid, ranging from 150 to 499 mg/dL. In addition, they either had "established cardiovascular disease," or they had Type 2 diabetes and at least one other cardiovascular risk factor. Patients were followed for a median 4.9 years.

Weintraub said that while there have been plenty of studies on statins and cholesterol, triglycerides haven't gotten the same attention on their own -- part of what makes this trial unique.

"I've always viewed triglycerides as the Rodney Dangerfield of lipids -- they didn't get enough respect," he said.

Still, he said it's unclear whether the drug prevents cardiovascular events by acting directly on triglycerides, or whether they are a marker for some other process going on in our bodies -- "secret sauce," as he says. Or perhaps some combination of the two, he added.

The company described the drug as "well tolerated," with "similar" rates of adverse events between those who got the drug and those who received a placebo.

The drug was approved by the US Food and Drug Administration in 2012 to lower triglycerides in excess of 500 mg/dL.

Roughly a quarter of Amercans age 20 and older have elevated triglycerides, according to data from the National Health and Nutrition Examination Survey. High triglycerides are associated with an increased risk of cardiovascular disease in combination with low HDL and high LDL, according to the US Centers for Disease Control and Prevention. The agency says lifestyle choices can help lower triglycerides, including exercise, weight loss, diet and quitting smoking.

Heart disease is the top cause of death in the US, leading to the deaths of more than 600,000 per year.

"There's still some debate on how important [triglycerides are], but I've gradually come to the opinion that it is important. But whether treating it is important -- there are a bunch of trials that have been, at best, ambiguous about that," Luepker said.

A bottle of 120 1-gram capsules of Vascepa has an average cash price of nearly $350, though many consumers will likely pay less, according to GoodRx, whose numbers are based on sources including published price lists, purchases, claims records and pharmacy data.

Weintraub said that the topline results may have granted a sneak peek, but that's hardly the end of the story. A deeper dive into the data could help illuminate whose risk was slashed the most, to what degree, and what other differences were seen between subgroups in the trial. For example, do the people with the highest triglycerides derive the greatest benefit? Is the effect the same in men and women, in people with or without diabetes?

"It may turn out to be worthwhile," said Luepker, but the announcement "does not give me enough information to make a reasoned judgment of whether this is good, bad or indifferent."

Weintraub, however, said that he wouldn't hesitate to prescribe the drug to patients like those in the trial, given what he described as a very favorable side effect profile and strong topline results.

"I would do it in a heartbeat," he said.

Minnesota Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 55947

Reported Deaths: 1654
CountyConfirmedDeaths
Hennepin17789819
Ramsey6861261
Dakota3942102
Anoka3327112
Stearns281720
Washington188643
Nobles17456
Olmsted162023
Scott136214
Mower10782
Rice9898
Blue Earth8485
Wright8015
Carver7692
Clay74340
Kandiyohi6701
Sherburne6387
St. Louis42719
Todd4182
Lyon4153
Freeborn3541
Steele3271
Nicollet30713
Benton3043
Watonwan2980
Winona24516
Crow Wing20613
Martin2035
Le Sueur1991
Beltrami1910
Chisago1761
Goodhue1758
Otter Tail1753
Cottonwood1710
Pipestone1439
Becker1421
McLeod1350
Unassigned13540
Douglas1290
Itasca12912
Polk1293
Waseca1280
Pine1260
Carlton1240
Dodge1220
Murray1221
Isanti1080
Chippewa971
Brown832
Meeker832
Morrison831
Faribault820
Sibley782
Wabasha780
Koochiching733
Rock730
Jackson700
Pennington701
Mille Lacs643
Fillmore610
Cass582
Renville585
Lincoln540
Swift521
Grant491
Yellow Medicine490
Roseau450
Houston400
Pope390
Norman340
Redwood300
Aitkin280
Hubbard280
Kanabec281
Marshall280
Wilkin283
Mahnomen231
Wadena230
Big Stone220
Red Lake190
Lake170
Stevens150
Clearwater140
Traverse100
Lac qui Parle60
Kittson40
Cook20
Lake of the Woods10

Iowa Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 45592

Reported Deaths: 877
CountyConfirmedDeaths
Polk9709202
Woodbury364250
Black Hawk299762
Linn208987
Johnson191815
Dallas178735
Buena Vista178412
Scott159012
Dubuque152729
Marshall138324
Pottawattamie121223
Story111013
Wapello84531
Muscatine82448
Crawford7153
Webster7125
Sioux5932
Cerro Gordo58117
Tama53729
Warren5261
Jasper45424
Plymouth4438
Wright4411
Louisa37814
Dickinson3754
Clinton3123
Washington28710
Hamilton2391
Boone2282
Franklin2134
Bremer1877
Clarke1853
Carroll1811
Emmet1791
Clay1711
Hardin1660
Shelby1591
Marion1520
Allamakee1494
Poweshiek1468
Benton1421
Des Moines1392
Jackson1391
Mahaska13617
Guthrie1265
Floyd1242
Jones1231
Cedar1201
Hancock1162
Butler1132
Pocahontas1131
Henry1123
Buchanan1101
Lyon1000
Madison1002
Cherokee971
Clayton973
Harrison960
Taylor930
Lee923
Delaware901
Monona900
Humboldt891
Iowa881
Winneshiek821
Calhoun812
Mills810
Sac810
Fayette790
Jefferson780
Palo Alto780
Kossuth770
Osceola770
Mitchell760
Page740
Winnebago730
Grundy721
Union701
Monroe667
Worth610
Chickasaw500
Davis491
Howard480
Cass471
Appanoose433
Lucas434
Montgomery433
Greene380
Fremont360
Van Buren311
Keokuk301
Ida290
Audubon281
Decatur210
Ringgold211
Adair200
Adams160
Wayne151
Unassigned70
Rochester
Scattered Clouds
67° wxIcon
Hi: 68° Lo: 47°
Feels Like: 67°
Mason City
Few Clouds
71° wxIcon
Hi: 71° Lo: 50°
Feels Like: 71°
Albert Lea
Scattered Clouds
66° wxIcon
Hi: 69° Lo: 50°
Feels Like: 66°
Austin
66° wxIcon
Hi: 69° Lo: 48°
Feels Like: 66°
Charles City
Broken Clouds
68° wxIcon
Hi: 69° Lo: 50°
Feels Like: 68°
Starting the week of dry
KIMT Radar
KIMT Eye in the sky

Latest Video

Image

Community adapting to changes at Rochester parks

Image

Fire-related fatalities increase in Minnesota

Image

Sean's Weather 8/3

Image

Campaign signs in Albert Lea

Image

Campaign signs go missing in Albert Lea

Image

Run the Woods race

Image

Don Bosco scores two in the 6th, stuns Newman for state title

Image

Pine Island holds community resource drive

Image

Pop up event for the homeless

Image

Seans 8/1 Weather

Community Events